{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017827","form_type":"8-K","ticker":"HIND","cik":"0001427570","company_name":"Vyome Holdings, Inc","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.618443+00:00","generated_at":"2026-06-21T19:49:35.862675+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ReShape Q3 revenue down 24.5% to $2.8M; non-GAAP adj. EBITDA loss $4.3M","bullets":["Revenue $2.8M for Q3 2022, down 24.5% YoY from $3.7M due to European sales decline.","Gross margin improved to 75.1% from 57.6%, driven by higher domestic sales mix and cost cuts.","Non-GAAP adjusted EBITDA loss widened to $4.3M from $3.6M in Q3 2021.","Cash and equivalents $6.1M as of Sep 30, 2022; company remains debt-free.","Appointed new CEO Paul F. Hickey in August; received FDA 510(k) clearance for GIBI HD tube."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017827","json":"https://secwatch.observer/filing/0001558370-22-017827.json","markdown":"https://secwatch.observer/filing/0001558370-22-017827.md","text":"https://secwatch.observer/filing/0001558370-22-017827.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427570/000155837022017827/0001558370-22-017827-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427570/000155837022017827/rsls-20221114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:49:35.862675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6060b1f7284c12f1d757b1fccd9ce1280d69e694","claim":"Vyome Holdings, Inc reported financial results for the three and nine months ended September 30, 2022.","evidence_excerpt":"ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the third quarter ended September 30, 2022 and provided a corporate strategic update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1427570/000155837022017827/0001558370-22-017827-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}